Pure Global AI
NCT06276283Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

A Phase II, Single Arm, Multicenter Study to Assess the Safety, Tolerability and Anti-Tumor Efficacy of DZD9008 With Bevacizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations (WU-KONG29)
Dizal PharmaceuticalsPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-small Cell Lung Cancer
Drug/Device/Intervention
DZD9008 plus Bevacizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Dizal Pharmaceuticals
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Feb 15, 2023
End date
Feb 28, 2026
Enrollment
60 participants
Primary outcome

Part A: 1) Dose Limiting Toxicity (DLT); 2) Treatment-Emergent Adverse Events (TEAEs); TEAEs ≥CTCAE grade 3; and Serious Adverse Events (SAEs). Part B: 1) TEAEs; TEAEs ≥CTCAE grade 3; and SAEs.

Summary

This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with
 advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care,
 which aims to understand whether the combination therapy is safe, how well the combination
 therapy works, and how the body will process DZD9008 when used in combination with
 bevacizumab.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06276283
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06276283 through Pure Global AI's free database. This Phase 2 trial is sponsored by Dizal Pharmaceuticals and is currently Recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.